Wasu Mekniran

Wasu Mekniran

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in BMC Public Health
Verified
Journal Article
Open access
WMWasu Mekniran
Wasu Mekniran
OGOdile-Florence Giger
Odile-Florence Giger
EFElgar Fleisch
Elgar Fleisch
TKTobias Kowatsch
Tobias Kowatsch
MJMia Jovanova
Mia Jovanova
Objective: Global population aging presents significant economic and social challenges, requiring coordinated efforts to enhance healthy lifespans. However, little is known about how stakeholders prioritize healthy aging initiatives. We aimed to examine how a sample of stakeholders prioritize determinants of healthy aging, and what gaps or inconsistencies exist in stakeholder focus on these determinants? Methods: We conducted a first systematic analysis of the value propositions of 56 stakeholders, including governments, companies, research centers, opinion leaders, communities, and multilateral organizations, identified through Web of Science, PitchBook, and Crunchbase. Guided by the National Academy of Medicine’s All-of-Society framework, we assessed stakeholder emphasis on four determinants of healthy aging: public health systems, social factors, physical infrastructure, and work and education. Results: Public health system reform emerged as the most emphasized determinant, with significant focus on investing in geroscience and developing tailored primary care for older adults. In contrast, critical social and infrastructural factors—such as digital literacy, housing, transportation, financial security, and loneliness—received limited attention among stakeholders. Conclusions: These findings highlight the need for cross-sector partnerships to address these overlooked determinants and ensure a holistic approach to healthy aging. Future research should explore collaborative strategies to bridge these gaps to meet the diverse needs of aging populations.

26 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
OGOdile-Florence Giger
Odile-Florence Giger
EPEstelle Pfitzer
Estelle Pfitzer
WMWasu Mekniran
Wasu Mekniran
HGHannes Gebhardt
Hannes Gebhardt
EFElgar Fleisch
Elgar Fleisch
TKTobias Kowatsch
Tobias Kowatsch
Background The global prevalence of diabetes is increasing and has stimulated new technological advancements in disease management. Although there are many digital health companies with a focus on diabetes, building them up at scale is difficult due to a heterogeneous, inefficient, and fragmented healthcare system. While ecosystems, or collaborative value creation, could help address system fragmentation; the current diabetes ecosystem remains not fully understood. Therefore, this paper analyzes the digital transformation of the diabetes ecosystem and deducts innovation patterns. We address the following research questions: (1) What are emerging organizations in the current diabetes ecosystem? (2) What are the value streams in the current diabetes ecosystem? (3) Which innovation patterns are present in the ecosystem? Methods We conduct a literature review and a market analysis to describe the organizations and value streams in the diabetes ecosystem, both before and after the digital transformation. We visualize the diabetes ecosystem using the e3-value methodology (RQ1 and RQ2). Next, expert interviews are conducted to validate the resulting diabetes ecosystem and deduce innovation patterns (RQ3). Results First, we show that the digital transformation gives rise to emerging organizations across eight segments: real-world evidence analytics, healthcare management platforms, clinical decision support, diagnostic and monitoring, digital therapeutics, wellness, online community, online pharmacy (RQ1). Secondly, we visualize the value streams between emerging organizations in the current diabetes ecosystem, highlighting the key role of patient data as currency (RQ2). Ultimately, we derive four innovation patterns in the current diabetes ecosystem (RQ3); namely open ecosystem strategy, outcome-based payments, platformization (connecting stakeholders), and user-centric software. Conclusions We demonstrate how traditional value chains in the diabetes ecosystem transition to platforms and outcome-based payment models, guiding strategic decisions for companies and healthcare providers. These innovation patterns may apply to similar ecosystems in other disease areas, aiding organizations in forecasting future dynamics.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
WMWasu Mekniran
Wasu Mekniran
WDWilma Diethelm
Wilma Diethelm
VSVictoire Stalder
Victoire Stalder
EFElgar Fleisch
Elgar Fleisch
TKTobias Kowatsch
Tobias Kowatsch
MJMia Jovanova
Mia Jovanova
Background: Type-2 diabetes (T2D) is largely preventable through sustained lifestyle change, yet healthcare systems face challenges in implementing and sustaining lifestyle interventions at scale. Digital health technologies (DHTs), offering personalized risk assessments, remote monitoring, and behavior change support, may support T2D prevention. However, the systemic role of DHTs within the T2D prevention ecosystem remains poorly understood. This study examines (RQ1) What stakeholder incentives are associated with prevention engagement among payers, providers, and individuals? (RQ2) What incentive patterns are associated with DHT adoption in T2D prevention? (RQ3) How is DHT adoption associated with value exchange among stakeholders in the T2D prevention ecosystem? Methods: We conducted a systematic literature review to identify existing incentives in preventive care (RQ1). Business model data from leading DHT companies in T2D prevention (via PitchBook and Crunchbase) were analyzed to examine emerging incentive patterns (RQ2). We conducted expert interviews ( N = 26) and synthesized findings using the e3-value framework to map stakeholder relationships (RQ3). Results: Our findings show that financial and non-financial incentives for prevention are often temporally misaligned. Engagement in lifestyle-based prevention is linked to short-term rewards, health, and convenience benefits for individuals and long-term cost savings for payers. DHT adoption for T2D prevention is associated with three key patterns: enhancing personalization and convenience for individuals, supporting value-based payment models for payers, and improving workflow efficiency for providers. Conclusions: DHTs may help align stakeholder incentives by promoting (1) sustained engagement in lifestyle prevention programs (i.e., continuous glucose monitoring with real-time dietary or activity feedback) and providing individuals with micro-rewards (i.e., for behavior change and improved clinical outcomes). These coordinated feedback loops could be embedded within (2) outcome-based reimbursements for payers and linked to (3) automated workflows to improve provider efficiency (i.e., risk stratification). Realizing this potential requires updated reimbursement models, integrated stakeholder coordination, and supportive policy frameworks.

11 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
WMWasu Mekniran
Wasu Mekniran
VBVictoria Bruegger
Victoria Bruegger
MFMagdalena Fuchs
Magdalena Fuchs
QJQiuhan Jin
Qiuhan Jin
BWBenjamin Wirth
Benjamin Wirth
MJMia Jovanova
Mia Jovanova
Objectives: Digital biomarkers offer scalable screening for type 2 diabetes, yet adoption is stalled by uncertainty regarding economic viability. This study evaluates the cost-effectiveness and budget impact of digital screening compared to opportunistic screening from a Swiss payer perspective. Methods: A probabilistic Markov cohort model was developed to simulate at-risk Swiss adults (age ≥45, BMI ≥25 kg/m²) over a 40-year horizon. The model incorporates a digital attrition parameter, inputs derived from Swiss-specific sources (e.g., the CoLaus study and FSO life tables), and statutory tariffs. Costs and outcomes were discounted at 3.0%. Results: In the deterministic base-case, digital screening yielded an incremental cost-effectiveness ratio of CHF 2,912 per quality-adjusted life-year gained. Probabilistic sensitivity analysis indicated a 93.2% probability of cost-effectiveness at the CHF 50,000 threshold. The budget impact analysis estimated a Year 1 gross investment budget of CHF 27 million to identify prevalent cases, followed by long-term savings from averted complications. Conclusions: Digital screening can be highly cost-effective in Switzerland. While the required Year 1 gross investment poses a liquidity challenge, reimbursement via pathway-oriented models under the Swiss tariff could align incentives with long-term complication avoidance.

28 January 2026 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
WMWasu Mekniran
Wasu Mekniran
TKTobias Kowatsch
Tobias Kowatsch
Background: Type 2 diabetes (T2D) represents a rapidly growing public health and economic burden. Although early intervention can reverse the progression of prediabetes, traditional risk screening remains underutilized. Digital biomarkers derived from smartphones and wearables offer scalable real-time detection, yet financial barriers constrain their integration into health systems. This study assesses the viability of a Business-to-Consumer (B2C) digital diabetes screening venture within the Swiss healthcare system. Methods: The Innovating in Healthcare Framework was applied to evaluate system alignment across six factors: structure, financing, public policy, technology, consumers, and accountability. Financial viability was modeled using a Monte Carlo program for probabilistic breakeven estimation, and one- and two-way sensitivity analyses for key funnel, price, and CAC variables. A discounted cash flow model assessed value creation. Sustainability was evaluated across four dimensions: revenue potential, cost efficiency, managerial scalability, and technological adaptability. Results: The venture showed strong alignment with consumer readiness, technology, and accountability, but weak fit in financing, public policy, and system structure. Financial modeling indicated positive cash flow in Year 4, with a 57% probability of breakeven within seven years. At 2917 users in Year 7, cumulative cash flow was slightly below zero. Profitability becomes feasible only when price ≥CHF 40, CAC ≤CHF 200, and screening participation ≥10%. Against a-priori thresholds, breakeven probability and NPV remain insufficient, while IRR often exceeds 20%. Long-term viability requires these conditions or transitioning to reimbursed B2B pathways. Conclusions: A B2C model can reach financial viability under favorable price and acquisition thresholds, but its long-term sustainability ultimately depends on regulatory validation that enables reimbursement.

6 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
WMWasu Mekniran
Wasu Mekniran
WWWeilan Wang
Weilan Wang
JAJonas John Posko Amalaraj
Jonas John Posko Amalaraj
JTJianhua Tay
Jianhua Tay
MZMoran Zhou
Moran Zhou
HMHans J. Meij
Hans J. Meij
This study examined the impact of perceived longevity on individual wealth allocation in Singapore. A cross-sectional survey of 299 adults, recruited via convenience and snowball sampling, assessed the trade-offs between personal health investment, family support, and societal contribution. Descriptive statistics and multiple regression identified demographic patterns. Sixty-six percent reported incorporating life expectancy into financial planning, with consistent prioritization of health and family across age, income, and ethnicity. Strong public support was expressed for increased government investment in preventive care and cost containment. These findings suggest that longevity awareness substantially influences financial decision-making in aging, high-income societies.